Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Shannon N Westin, MD

NRG Oncology

Intervention

Laboratory Biomarker Analysis(other)

Enrollment

26 enrolled

Eligibility

18 years · FEMALE

Timeline

2013 – 2015

Study locations (22)

• Hartford Hospital, Hartford, Connecticut, United States
• The Hospital of Central Connecticut, New Britain, Connecticut, United States
• Augusta University Medical Center, Augusta, Georgia, United States
• University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
• University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
• Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States
• Case Western Reserve University, Cleveland, Ohio, United States
• Cleveland Clinic Foundation, Cleveland, Ohio, United States
• Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
• Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States
• University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
• +7 more locations on ClinicalTrials.gov

Collaborators

NRG Oncology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.